Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NightRest: Gabapentin Enacarbil for Agitation in Alzheimer's
NCT03082755Phase 4Recruiting
- Sponsor
- University of Texas at Austin
- Start
- Jul 2017
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in restless legs syndrome (RLS) comparing Gabapentin Enacarbil with Placebo (2 arms). Primary endpoint: Nighttime Agitation - Cohen Mansfield Agitation Inventory (CMAI) - Direct Observation at 8 weeks. Started Jul 2017; status: recruiting.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT03082755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082755.